IceCure Medical Marks Milestone in Kidney Cancer Cryoablation Study with 5-Year Follow-Up Outcomes

IceCure Medical Achieves Major Milestone in ICESECRET Study of Kidney Cancer Treatment

IceCure Medical Ltd. (Nasdaq: ICCM), a leading innovator in minimally-invasive cryoablation technology, has proudly completed its five-year follow-up evaluations in the ICESECRET clinical trial. This essential study assesses the effectiveness of ProSense® in treating small renal masses (SRMs) in kidney cancer patients. The final analysis of the extensive data collected is expected to be released in the second quarter of 2026.

The ICESECRET trial represented a pioneering multicenter, single-arm clinical evaluation, taking place at two prominent hospitals in Israel: Bnai Zion Medical Center in Haifa and Shamir Medical Center in Be'er Ya'akov. Under the leadership of Principal Investigator Prof. Halahmi Sarel, the study initially enrolled 114 patients with localized SRMs under 5 cm, employing ProSense® cryoablation guided by CT imaging. Follow-up assessments occurred at six-week, six-month, one-year, and then annually up to five years post-procedure, enabling the collection of crucial data regarding recurrence rates and safety.

Eyal Shamir, the Chief Executive Officer of IceCure, noted, “The interim three-year data we presented a year ago showed ProSense® cryoablation’s strong potential as a safe and effective alternative for patients who are not candidates for conventional kidney-preserving surgeries. There is a growing unmet need for such options.” With regulatory approvals secured in key markets including both the U.S. and Europe, IceCure is committed to advancing the application of its innovative technology.

The necessity for advanced treatment solutions intensifies as the incidence of kidney cancer continues to rise worldwide, with an alarming estimate of 400,000 new cases annually. The increasing detection of SRMs has brought about significant clinical challenges, particularly for older patients or those with comorbidities who may be ineligible for surgery. Such considerations underscore the critical demand for minimally invasive treatments which not only manage tumor growth but also protect kidney function.

Overview of ProSense®

ProSense® Cryoablation System is the only medical device that holds FDA marketing authorization for the local treatment of low-risk breast cancer for women aged 70 and over, and has shown promise in various other applications, including kidney cancer. This minimally invasive tool utilizes liquid nitrogen to effectively freeze tumors, thus creating large lethal zones conducive to tumor destruction.

By promoting shorter recovery times and minimizing surgical risks, ProSense® enhances the overall patient experience while ensuring effective tumor management. Its efficient design allows easy portability, making office-based procedures for various tumors a feasible reality.

Impact of IceCure Medical

IceCure Medical focuses on developing state-of-the-art, liquid-nitrogen-based cryoablation technologies for tumor treatment. With the ProSense® system being marketed globally, the company aims to expand its reach and enable more patients to access this life-saving technology.

The clinical community eagerly anticipates the upcoming final analysis of the ICESECRET trial data, which promises to further validate the efficacy and safety of the ProSense® system in treating kidney cancer. As IceCure Medical continues to pursue advancements in treatment methodologies, it positions itself at the forefront of innovation in the healthcare sector, aiming to address an urgent need for better treatment options for cancer patients.

Looking Ahead

In summary, the completion of the five-year follow-up in the ICESECRET study exemplifies IceCure Medical's ongoing dedication to addressing critical challenges in kidney cancer treatment. The forthcoming analysis is expected to offer invaluable insights, paving the way for enhanced, patient-centered care.

As the healthcare landscape evolves, the innovative solutions from IceCure Medical could significantly reshape patient outcomes in kidney cancer and other malignancies, representing a paradigm shift towards safer, less invasive treatments.